Effect of co-targeting pathways on histopathology in mCMV-infected NB + 12 SMGs. A. Control SMG. B-F. mCMV-infected SMGs. mCMV-infected SMGs (B) show pathology composed of abnormal epithelia and viral CPE in the stroma. GEF-treated, mCMV-infected SMGs treated with U0126 beginning on day 6 (CMV + GEF + D6U) (C) exhibit progressive pathology but continues to present decreased branching and stromal pathology with viral CPE (arrowhead) (compare C to B). Inset: Higher magnification of mCMV-infected and affected stromal cells. U0126-treated, mCMV-infected SMGs treated with GEF beginning on day 6 (CMV + U + D6 GEF) (D) exhibit progressive pathology and demonstrates improved epithelial morphology and branching (compare D to B, C), with continued viral CPE in stroma (arrowhead) being seen (compare D to A). Inset: Higher magnification of mCMV-infected and affected stromal cells. GEF-treated, mCMV-infected SMG (E) treated with aciclovir beginning on day 6 (CMV + GEF + D6 Acy) demonstrate a near normal morphology of extensive epithelial branching, abundant serous acini, and a fibromyxoid stroma (compare E to A). Right Inset: Higher magnification of stromal stellate fibroblasts. Left Inset: Higher magnification of serous acini. U0126-treated, mCMV-infected SMG (F) treated with aciclovir beginning on day 6 (CMV + U + D6 Acy) demonstrate a near normal morphology, composed of a highly branched epithelia in a fibromyxoid stroma approximating control SMGs (compare F to A). Inset: Higher magnification of stromal stellate fibroblasts. Bar: A-F, 50 μm; Insets C, D, F - 25 μm. E, left inset- 30 μm; right inset - 25 μm.